• 1
    Buzaid AC,Bedikian A,Houghton AN. Systemic chemotherapy and biochemotherapy. In: BalchCM,HoughtonAN,SoberAJ,SoongS-J, eds. Cutaneous Melanoma. St. Louis, Mo: Quality Medical Publishing; 1998: 405418.
  • 2
    Chapman PB,Einhorn LH,Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999; 17: 27452751.
  • 3
    Royal RE,Steinberg SM,Krouse RS, et al. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am. 1996; 2: 91.
  • 4
    Atkins MB,Lotze MT,Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17: 21052116.
  • 5
    Kirkwood JM,Strawderman MH,Ernstoff MS,Smith TJ,Borden EC,Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14: 717.
  • 6
    Kirkwood JM,Ibrahim JG,Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000; 18: 24442458.
  • 7
    Kirkwood JM,Ibrahim JG,Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001; 19: 23702380.
  • 8
    Falkson CI,Ibrahim J,Kirkwood JM,Coates AS,Atkins MB,Blum RH. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998; 16: 17431751.
  • 9
    Atkins MB,Lee S,Flaherty LE,Sosman JA,Sondak VK,Kirkwood JM. A prospective randomized phase III trial of concurrent biochemotherapy (BCT) with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha-2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): an ECOG-coordinated intergroup trial. Proc Am Soc Clin Oncol. 2003: 22: 708. Abstract 2847.
  • 10
    Byrd DM,Roegner ML,Griffiths JC, et al. Carcinogenic risks of inorganic arsenic in perspective. Int Arch Occup Environ Health. 1996; 68: 484494.
  • 11
    Shen ZX,Chen GQ,Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89: 33543360.
  • 12
    Soignet SL,Maslak P,Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998; 339: 13411348.
  • 13
    Soignet SL,Frankel SR,Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001; 19: 38523860.
  • 14
    Islam M,Kirkwood JM. Arsenic trioxide induces apoptosis of human melanoma cell lines in-vitro. Proc Am Soc Clin Oncol. 2001. Abstract 1435.
  • 15
    Ivanov VN,Hei TK. Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway. J Biol Chem. 2004; 279: 22,747–22,758.
  • 16
    Shen ZY,Tan LJ,Cai WJ, et al. Arsenic trioxide induces apoptosis of esophageal carcinoma in vitro. Int J Mol Med. 1999; 4: 3337.
  • 17
    Rousselot P,Labaume S,Marolleau JP, et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res. 1999; 59: 10411048.
  • 18
    Zhang W,Ohnishi K,Shigeno K, et al. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms. Leukemia. 1998; 12: 13831391.
  • 19
    Lu M,Levin J,Sulpice E, et al. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol. 1999; 27: 845852.
  • 20
    Akao Y,Mizoguchi H,Kojima S,Naoe T,Ohishi N,Yagi K. Arsenic induces apoptosis in B-cell leukemic cell lines in vitro: activation of caspases and down-regulation of Bcl-2 protein. Br J Haematol. 1998; 102: 10551060.
  • 21
    Hershko DD,Robb BW,Hungness ES,Luo G,Hasselgren PO. Arsenite stabilizes IkappaBalpha and prevents NF-kappaB activation in IL-1 beta-stimulated Caco-2 cells independent of the heat shock response. J Cell Biochem. 2002; 84: 687698.
  • 22
    Li YM,Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res. 1999; 59: 776780.
  • 23
    Huang C,Ma WY,Li J,Dong Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res. 1999; 59: 30533058.
  • 24
    Larochette N,Decaudin D,Jacotot E, et al. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res. 1999; 249: 413421.
  • 25
    Chen YC,Lin-Shiau SY,Lin JK. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol. 1998; 177: 324333.
  • 26
    Chen GQ,Zhu J,Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996; 88: 10521061.
  • 27
    Dai J,Weinberg RS,Waxman S,Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 1999; 93: 268277.
  • 28
    Mathas S,Lietz A,Janz M, et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood. 2003; 102: 10281034.
  • 29
    Soignet S,Bienvenu B,Cheung NK. Clinical and pharmacologic study of arsenic trioxide (As2O3) in patients with solid tumors. Proc Am Soc Clin Oncol. 2000. Abstract 784.
  • 30
    Fox E,Adamson P,Murgo A. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children with refractory leukemia. Proc Am Soc Clin Oncol. 2002. Abstract 1582.
  • 31
    Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 32
    Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 33
    Balch CM,Buzaid AC,Soong SJ, et al. Final version of theAmerican Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001; 19: 36353648.
  • 34
    Kim KB,Bedikian AY,Camacho LH,Papadopoulos NE,McCullough C. A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer. 2005; 104: 16871692.
  • 35
    Ahmad T,Marais R,Pyle L,Schwartz B,Gore M,Eisen T. BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. Proc Am Soc Clin Oncol. 2004. Abstract 7506.
  • 36
    Abou-Merhi R,Khoriaty R,Arnoult D, et al. PS-341 or a combination of arsenic trioxide and interferon-alpha inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells. Leukemia. 2007; 21: 17921801.
  • 37
    Campbell RA,Sanchez E,Steinberg JA, et al. Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol. 2007; 138: 467478.
  • 38
    Berenson JR,Matous J,Swift RA,Mapes R,Morrison B,Yeh HS. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res. 2007; 13: 17621768.